AMENDMENT NO. 4 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • October 30th, 2019 • Incyte Corp • Services-commercial physical & biological research
THIS AMENDMENT NO. 4 TO COLLABORATION AND LICENSE AGREEMENT (this “Amendment No. 4”) is entered into as of the 5th day of April, 2016 (the “Effective Date”), by and between Incyte Corporation, a Delaware corporation having an office at 1801 Augustine Cut-Off, Wilmington, Delaware (“Incyte”), and Novartis International Pharmaceutical Ltd., a limited company organized under the laws of Bermuda having an office at 131 Front Street, Hamilton, Bermuda HM 12 (“Novartis”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 30th, 2019 • Incyte Corp • Services-commercial physical & biological research • Delaware
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) by and between INCYTE CORPORATION, a Delaware corporation (the “Company”), and Hervé Hoppenot (the “Executive”), dated as of the 25th day of October, 2019.
COLLABORATION AND LICENSE AGREEMENT by and between Incyte Corporation Experimental Station, Route 141 & Henry Clay Road Wilmington, Delaware and Novartis International Pharmaceutical Ltd. 131 Front Street Hamilton, Bermuda HM 12Collaboration and License Agreement • October 30th, 2019 • Incyte Corp • Services-commercial physical & biological research
THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 24th day of November, 2009 (the “Effective Date”), by and between Incyte Corporation, a Delaware corporation having an office at Experimental Station, Route 141 & Henry Clay Road, Wilmington, Delaware (“Incyte”), and Novartis International Pharmaceutical Ltd., a limited company organized under the laws of Bermuda having an office at 131 Front Street, Hamilton, Bermuda HM 12 (“Novartis”).
AMENDMENTDevelopment and Commercialization Agreement • October 30th, 2019 • Incyte Corp • Services-commercial physical & biological research
This Amendment (“Amendment”) is entered into effective June 22, 2010 (the “Amendment Effective Date”) by and between Incyte Corporation, a Delaware Corporation having an office at Experimental Station, Route 141 & Henry Clay Road, Wilmington, Delaware (“Incyte”), and Eli Lilly and Company (“Lilly”), an Indiana corporation having an office at Lilly Corporate Center, Indianapolis, Indiana 46285.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between Incyte Corporation Experimental Station, Route 141 & Henry Clay Road Wilmington, Delaware and Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285License, Development and Commercialization Agreement • October 30th, 2019 • Incyte Corp • Services-commercial physical & biological research
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of the 18th day of December, 2009 (“Effective Date”), by and between Incyte Corporation, a Delaware corporation having an office at Experimental Station, Route 141 & Henry Clay Road, Wilmington, Delaware (“Incyte”), and Eli Lilly and Company, an Indiana corporation having an office at Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”).
